Amplia Therapeutics (ASX:ATX) has commenced trading on the U.S. OTCQB Venture Market under the ticker INNMF, expanding access for U.S. investors to the company’s common stock. The uplisting took effect on October 29, 2025, marking an important milestone in the company's strategy to enhance its international profile and investor engagement.
Amplia’s Managing Director and Chief Executive Officer, Dr Chris Burns, said the OTCQB listing would enable broader communication with investors at a time of growing global interest in the company’s work on Focal Adhesion Kinase (FAK) inhibitors and the development of new treatments for pancreatic cancer.
“The uplist to the OTCQB market enhances the company’s ability to productively engage with U.S. investors at a time when there is increasing interest in the FAK inhibitor space and in the development of drugs for pancreatic cancer,” Dr Burns said. “We believe this will provide additional opportunities to communicate with investors about the company’s progress, including clinical milestones and corporate and financial highlights.”
The OTCQB Venture Market, operated by OTC Markets Group, provides early-stage and developing companies with access to U.S. investors who can trade shares in U.S. dollars during U.S. market hours. Amplia will maintain its primary listing on the ASX under the codes ATX and ATXOA.
The move comes as Amplia advances its AMPLICITY trial in advanced pancreatic cancer, which is enrolling patients in Australia and will soon open at five clinical sites in the United States. The company has also expanded investor education and engagement efforts around its FAK inhibitor program as part of a broader capital markets campaign.
Amplia is an Australian biotechnology company developing a pipeline of FAK inhibitors for cancer and fibrosis, targeting diseases such as pancreatic and ovarian cancer, as well as idiopathic pulmonary fibrosis. Its lead candidate, Narmafotinib (AMP945), is a highly potent and selective inhibitor of FAK, demonstrating promising preclinical and clinical data.
The company’s ACCENT trial combines Narmafotinib with gemcitabine and Abraxane in patients with advanced pancreatic cancer, showing a 33 per cent response rate and an interim progression-free survival of 7.6 months, results that outperform chemotherapy alone. The AMPLICITY trial, now active in Australia and the U.S., is evaluating Narmafotinib in combination with the chemotherapy FOLFIRINOX.